SEC Form 4 · accession 0001385508-18-000111
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phil Skolnick
Officer — Chief Scientific Officer
Period of report
Nov 6, 2018
Accepted (ET)
Nov 8, 2018 · 4:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 6, 2018 | S | 3,217 | $16.81 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- F2This transaction was executed in multiple trades at prices ranging from $16.80 to $17.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.